Evidence map›Paper›PMID 26048536›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2015

Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis.

Liang Shen, Chun Ming Sun, Xue Tao Li, Chuan Jin Liu, You Xin Zhou

Open access · hybridAbstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 5 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Management of incidental brain tumors in children: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020
    Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Review
  9. Recent Advances in Pediatric Medulloblastoma.Current neurology and neuroscience reports · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Observational
  16. Observational
  17. Incidental brain tumors in children: an international neurosurgical, oncological survey.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018
    Article
  18. Review
  19. Malignant transformation of a conservatively managed incidental childhood cerebral mass lesion: controversy regarding management paradigm.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017
    Article
  20. Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS).Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Liang ShenDepartment of Neurosurgery, Huzhou Central Hospital, Huzhou, 313100, Zhejiang, China.
Chun Ming SunBrain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou, 215006, Jiangsu, China.
Xue Tao LiBrain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou, 215006, Jiangsu, China.
Chuan Jin LiuBrain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou, 215006, Jiangsu, China.
You Xin ZhouBrain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou, 215006, Jiangsu, China. 20125232086@suda.edu.cn.
First Affiliated Hospital of Soochow University · CNSoochow University · CNHuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth hormone deficiency is common in intracranial tumors, which is usually treated with surgery and radiotherapy. A number of previous studies have investigated the relationship between the growth hormone replacement therapy (GHRT) and risk of tumor recurrence/progression; however, the evidence remains controversial. We conducted a meta-analysis of published studies to estimate the potential relation between GHRT and intracranial tumors recurrence/progression. Three comprehensive databases, PUBMED, EMBASE, and Cochrane Library, were researched with no limitations, covering all published studies till the end of July, 2014. Reference lists from identified studies were also screened for additional database. The summary relative risks (RR) and 95% confidence intervals (CI) were calculated by fixed-effects models for estimation. Fifteen eligible studies, involving more than 2232 cases and 3606 controls, were included in our meta-analysis. The results indicated that intracranial tumors recurrence/progression was not associated with GHRT (RR 0.48, 95% CI 0.39-0.56), and for children, the pooled RR was 0.44 and 95% CI was 0.34-0.54. In subgroup analysis, risks of recurrence/progression were decreased for craniopharyngioma, medulloblastoma, astrocytoma, glioma, but not for pituitary adenomas, and non-functioning pituitary adenoma (NFPA), ependymoma. Results from our analysis indicate that GHRT decreases the risk of recurrence/progression in children with intracranial tumors, craniopharyngioma, medulloblastoma, astrocytoma, or glioma. However, GHRT for pituitary adenomas, NFPA, and ependymoma was not associated with the recurrence/progression of the tumors. GH replacement seems safe from the aspect of risk of tumor progression.

Indexed as

Hormone Replacement TherapyBrain NeoplasmsDisease ProgressionHuman Growth HormoneHumansNeoplasm Recurrence, LocalHuman Growth HormoneGrowth hormoneIntracranial tumorsMeta-analysisRecurrenceRisk

Identifiers

PMID26048536
OpenAlexW952220580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.